BCRX Q3 2020 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+243.8% YoY

Gross Profit

$5M75.0% margin

Operating Income

-$43M-702.5% margin

Net Income

-$46M-755.7% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

+112.5%

Cash Flow

Operating Cash Flow

-$38M

Free Cash Flow

-$38M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$176M

Total Liabilities

$143M

Stockholders' Equity

$34M

Cash & Equivalents

$96M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$2M	+243.8%
Gross Profit	$5M	$2M	+160.4%
Operating Income	-$43M	-$35M	-22.1%
Net Income	-$46M	-$38M	-22.7%

Revenue Segments

Collaborative and Other Research and Development

$3M55%

Product

$2M41%

Royalty

$254,0004%